Cancer journal最新文献_第10页

Tumor-Derived Exosomes and the Role of Liquid Biopsy in Human Papillomavirus Oropharyngeal Squamous Cell Carcinoma. 肿瘤来源的外泌体和液体活检在人乳头瘤病毒口咽鳞状细胞癌中的作用。

IF 2.2 4区医学

Cancer journal Pub Date : 2023-07-01 DOI: 10.1097/PPO.0000000000000671

Michael M Allevato, Joshua D Smith, Michael J Brenner, Steven B Chinn

{"title":"Tumor-Derived Exosomes and the Role of Liquid Biopsy in Human Papillomavirus Oropharyngeal Squamous Cell Carcinoma.","authors":"Michael M Allevato, Joshua D Smith, Michael J Brenner, Steven B Chinn","doi":"10.1097/PPO.0000000000000671","DOIUrl":"10.1097/PPO.0000000000000671","url":null,"abstract":"Abstract: The global incidence of human papillomavirus-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) has surged in recent decades, with HPV+ HNSCC accounting for >70% of oropharynx cancers in the United States. Its incidence in men has surpassed that of HPV+ cervical cancer in women, and reliable assays are needed for early detection and to monitor response to therapy. Human papillomavirus-positive OPSCC has a more favorable response to therapy and prognosis than HPV-negative (HPV-) HNSCC, motivating regimens to deintensify curative surgery or chemoradiotherapy protocols. A barrier to deintensifying and personalizing therapy is lack of reliable predictive biomarkers. Furthermore, HPV- HNSCC survival rates are static without reliable surveillance biomarkers available. The emergence of circulating plasma-based biomarkers reflecting the tumor-immune microenvironment heralds a new era in HNSCC diagnosis and therapy. We review evidence on tumor-derived extracellular vesicles (exosomes) as biomarkers for diagnosis, prognostication, and treatment in HPV+ and HPV- HNSCC.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 4","pages":"230-237"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9884051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating Tumor DNA in Human Papillomavirus-Mediated Oropharynx Cancer: Leveraging Early Data to Inform Future Directions. 人类乳头瘤病毒介导的口咽癌症中的循环肿瘤DNA：利用早期数据为未来方向提供信息。

IF 2.2 4区医学

Cancer journal Pub Date : 2023-07-01 DOI: 10.1097/PPO.0000000000000670

Molly E Heft Neal, Heather M Walline, Catherine T Haring

引用次数: 0

Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment. 骨髓增生异常综合征治疗的新方法和未来方向。

IF 2.2 4区医学

Cancer journal Pub Date : 2023-05-01 DOI: 10.1097/PPO.0000000000000658

Jan Philipp Bewersdorf, Zhuoer Xie, Amer M Zeidan

{"title":"Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment.","authors":"Jan Philipp Bewersdorf, Zhuoer Xie, Amer M Zeidan","doi":"10.1097/PPO.0000000000000658","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000658","url":null,"abstract":"Abstract: Myelodysplastic syndromes/neoplasms (MDSs) constitute a heterogeneous group of clonal disorders that are clinically characterized by dysplastic changes in multiple hematopoietic lineages, cytopenias, and a variable risk of progression to acute myeloid leukemia. Patients with MDS are classified as either lower- or higher-risk based on risk stratification tools such as the International Prognostic Scoring System and its revised version, which continue to be the basis for prognosis and treatment selection. Although anemic patients with lower-risk MDS are currently treated with an erythropoiesis-stimulating agent, luspatercept, and transfusions, the telomerase inhibitor imetelstat and the hypoxia-inducible factor α inhibitor roxadustat have shown encouraging early results and are now in phase III clinical trials. For higher-risk MDS patients, hypomethylating agent monotherapy continues to be the standard of care. However, with various novel hypomethylating agent-based combination therapies in advanced clinical testing and an increased emphasis on individualized biomarker-driven treatment decisions, the standard therapy paradigms might change in the future.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 3","pages":"195-202"},"PeriodicalIF":2.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9498193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in Classification of Myelodysplastic Syndrome. 骨髓增生异常综合征分类的最新进展。

IF 2.2 4区医学

Cancer journal Pub Date : 2023-05-01 DOI: 10.1097/PPO.0000000000000659

Mina L Xu, Robert P Hasserjian

引用次数: 0

Epidemiology and Pathogenesis of Myelodysplastic Syndrome. 骨髓增生异常综合征的流行病学和发病机制。

IF 2.2 4区医学

Cancer journal Pub Date : 2023-05-01 DOI: 10.1097/PPO.0000000000000665

Lara K Rotter, Shai Shimony, Kelly Ling, Evan Chen, Rory M Shallis, Amer M Zeidan, Maximilian Stahl

{"title":"Epidemiology and Pathogenesis of Myelodysplastic Syndrome.","authors":"Lara K Rotter, Shai Shimony, Kelly Ling, Evan Chen, Rory M Shallis, Amer M Zeidan, Maximilian Stahl","doi":"10.1097/PPO.0000000000000665","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000665","url":null,"abstract":"Abstract Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal hematopoiesis (CH) to CH of indeterminate potential, clonal cytopenia of unknown significance, to frank MDS. The molecular heterogeneity seen in MDS is highly complex and includes mutations of genes involved in splicing machinery, epigenetic regulation, differentiation, and cell signaling. Recent advances in the understanding of the molecular landscape of MDS have led to the development of improved risk assessment tools and novel therapies. Therapies targeting the underlying pathophysiology will hopefully further expand the armamentarium of MDS therapeutics, bringing us closer to a more individualized therapeutic approach based on the unique molecular profile of each patient and eventually improving the outcomes of patients with MDS. We review the epidemiology of MDS and the newly described MDS precursor conditions CH, CH of indeterminate potential, and CCUS. We then discuss central aspects of MDS pathophysiology and outline specific strategies targeting hallmarks of MDS pathophysiology, including ongoing clinical trials examining the efficacy of these therapeutic modalities.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 3","pages":"111-121"},"PeriodicalIF":2.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9498187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. 从克隆造血到骨髓增生异常肿瘤/综合征和其他髓系肿瘤的频谱。

IF 2.2 4区医学

Cancer journal Pub Date : 2023-05-01 DOI: 10.1097/PPO.0000000000000656

Zhuoer Xie, Evan C Chen, Lourdes M Mendez, Rami Komrokji, Amer M Zeidan

引用次数: 0

Supportive Care for Patients With Myelodysplastic Syndromes. 骨髓增生异常综合征患者的支持治疗。

IF 2.2 4区医学

Cancer journal Pub Date : 2023-05-01 DOI: 10.1097/PPO.0000000000000661

Jessica M Stempel, Nikolai A Podoltsev, Talib Dosani

引用次数: 0

Myelodysplastic Syndromes/Neoplasms-Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments. 骨髓增生异常综合征/肿瘤-导致改进分类，风险分层和治疗的发病机制的见解。